• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

乌司他丁治疗新型冠状病毒肺炎的疗效：一项回顾性研究

Efficacy of Ulinastatin in the Treatment of COVID-19: A Retrospective Study.

作者信息

Liu Peng, Wu Qi, Li Mengjie

机构信息

School of Graduate, Tianjin Medical University, Tianjin, People's Republic of China.

Department of Respiratory and Critical Care Medicine, Cangzhou Fifth Hospital (People's Hospital of Qingxian), Cangzhou, People's Republic of China.

出版信息

Int J Gen Med. 2024 Dec 24;17:6421-6430. doi: 10.2147/IJGM.S486434. eCollection 2024.

DOI:10.2147/IJGM.S486434
PMID:39735165
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11681785/
Abstract

PURPOSE

This retrospective study aimed to evaluate the efficacy of ulinastatin in the treatment of COVID-19 patients compared to conventional therapy.

PATIENTS AND METHODS

A total of 437 COVID-19 patients admitted to the Respiratory Oncology Department of our hospital between December 31, 2022, and July 8, 2023, were included in the study. Patients were classified into the observation group (n=62) receiving ulinastatin in addition to standard treatment and the control group (n=347) receiving standard treatment only. Clinical information, laboratory results, and treatment outcomes were collected and analyzed.

RESULTS

The observation group showed an improvement in lymphocyte count compared to the control group. The clinical improvement rate in patients receiving ulinastatin for 7 days or longer was 92.1%, significantly higher than that of patients treated for less than 7 days (62.5%) and those receiving standard treatment (71.0%). No significant difference in total length of hospitalization was observed between the two groups, and no related adverse events occurred in either group.

CONCLUSION

Ulinastatin treatment improves lymphocyte counts in severe COVID-19 patients, and the clinical improvement rate is significantly higher with treatment duration of 7 days or longer. Larger-scale randomized controlled trials are warranted to further explore the role of ulinastatin in the management of COVID-19.

摘要

目的

本回顾性研究旨在评估与传统疗法相比，乌司他丁治疗新型冠状病毒肺炎（COVID-19）患者的疗效。

患者与方法

纳入2022年12月31日至2023年7月8日期间我院呼吸肿瘤科收治的437例COVID-19患者。患者分为观察组（n=62），在标准治疗基础上加用乌司他丁；对照组（n=347），仅接受标准治疗。收集并分析临床信息、实验室检查结果及治疗结局。

结果

与对照组相比，观察组淋巴细胞计数有所改善。接受乌司他丁治疗7天及以上患者的临床改善率为92.1%，显著高于治疗时间不足7天的患者（62.5%）及接受标准治疗的患者（71.0%）。两组患者的总住院时长无显著差异，且两组均未发生相关不良事件。

结论

乌司他丁治疗可改善重症COVID-19患者的淋巴细胞计数，治疗7天及以上时临床改善率显著更高。有必要开展更大规模的随机对照试验，进一步探究乌司他丁在COVID-19治疗中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/0f501874807a/IJGM-17-6421-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/b9b7e33eb298/IJGM-17-6421-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/11fc540374ee/IJGM-17-6421-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/81174eef46ba/IJGM-17-6421-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/679a74dee033/IJGM-17-6421-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/0f501874807a/IJGM-17-6421-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/b9b7e33eb298/IJGM-17-6421-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/11fc540374ee/IJGM-17-6421-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/81174eef46ba/IJGM-17-6421-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/679a74dee033/IJGM-17-6421-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11681785/0f501874807a/IJGM-17-6421-g0005.jpg

相似文献

1
Efficacy of Ulinastatin in the Treatment of COVID-19: A Retrospective Study.乌司他丁治疗新型冠状病毒肺炎的疗效：一项回顾性研究
Int J Gen Med. 2024 Dec 24;17:6421-6430. doi: 10.2147/IJGM.S486434. eCollection 2024.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Effect of probiotics combined with Ulinastatin and Somatostatin in the treatment of severe acute pancreatitis.益生菌联合乌司他丁和生长抑素治疗重症急性胰腺炎的疗效
Pak J Med Sci. 2024 Sep;40(8):1729-1734. doi: 10.12669/pjms.40.8.9744.
4
Treatment of patients with Covid-19 with a high dose of ulinastatin.用大剂量乌司他丁治疗新冠病毒肺炎患者。
Exp Ther Med. 2022 Feb;23(2):121. doi: 10.3892/etm.2021.11044. Epub 2021 Dec 7.
5
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性（COVA 研究）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
6
Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19.尿胰蛋白酶抑制剂（乌司他丁）治疗新型冠状病毒肺炎（COVID-19）的疗效
Indian J Crit Care Med. 2022 Jun;26(6):696-703. doi: 10.5005/jp-journals-10071-24156.
7
Ulinastatin combined with somatostatin enhances disease control and modulates serum inflammatory factors in patients with severe pancreatitis.乌司他丁联合生长抑素可增强重症胰腺炎患者的疾病控制并调节血清炎症因子。
Am J Transl Res. 2023 Sep 15;15(9):5797-5807. eCollection 2023.
8
Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).同种异体人牙髓干细胞治疗重症 COVID-19 患者的安全性和有效性评估：一项随机对照试验（I/II 期）研究方案的结构化总结
Trials. 2020 Jun 12;21(1):520. doi: 10.1186/s13063-020-04380-5.
9
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.双盲、随机、对照临床试验评估同种异体间充质基质细胞治疗 COVID-19 所致急性呼吸窘迫综合征患者的疗效（COVID-AT）：一项随机对照试验的研究方案的结构总结。
Trials. 2021 Jan 6;22(1):9. doi: 10.1186/s13063-020-04964-1.
10
Rationale and design of a prospective, multicentre, randomised, conventional treatment-controlled, parallel-group trial to evaluate the efficacy and safety of ulinastatin in preventing acute respiratory distress syndrome in high-risk patients.一项前瞻性、多中心、随机、常规治疗对照、平行组试验的原理和设计，旨在评估乌司他丁预防高危患者急性呼吸窘迫综合征的疗效和安全性。
BMJ Open. 2019 Mar 7;9(3):e025523. doi: 10.1136/bmjopen-2018-025523.

本文引用的文献

1
Expression of Angiopoietin-2 in Lung Tissue of Juvenile SD Rats with Lipopolysaccharide-Induced Acute Lung Injury and the Role of Ulinastatin.脂多糖诱导幼年 SD 大鼠急性肺损伤肺组织中血管生成素-2 的表达及尿胰蛋白酶抑制剂的作用。
Arch Immunol Ther Exp (Warsz). 2023 Oct 26;71(1):23. doi: 10.1007/s00005-023-00688-7.
2
Ulinastatin Add-on to Standard of Care in Critically Ill COVID-19 Patients: A Multicenter, Retrospective Study.乌司他丁联合标准治疗方案对危重症 COVID-19 患者的疗效：一项多中心回顾性研究。
J Assoc Physicians India. 2023 Feb;71(2):11-12. doi: 10.5005/japi-11001-0181.
3
The development of COVID-19 treatment.
COVID-19 治疗的发展。
Front Immunol. 2023 Jan 26;14:1125246. doi: 10.3389/fimmu.2023.1125246. eCollection 2023.
4
Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19.尿胰蛋白酶抑制剂（乌司他丁）治疗新型冠状病毒肺炎（COVID-19）的疗效
Indian J Crit Care Med. 2022 Jun;26(6):696-703. doi: 10.5005/jp-journals-10071-24156.
5
Protective effect of Ulinastatin on acute lung injury in diabetic sepsis rats.乌司他丁对糖尿病脓毒症大鼠急性肺损伤的保护作用。
Int Immunopharmacol. 2022 Jul;108:108908. doi: 10.1016/j.intimp.2022.108908. Epub 2022 Jun 3.
6
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.关于具有治疗 SARS-CoV-2（COVID-19）潜力的药物的最新进展。
Drug Resist Updat. 2021 Dec;59:100794. doi: 10.1016/j.drup.2021.100794. Epub 2021 Dec 9.
7
Treatment of patients with Covid-19 with a high dose of ulinastatin.用大剂量乌司他丁治疗新冠病毒肺炎患者。
Exp Ther Med. 2022 Feb;23(2):121. doi: 10.3892/etm.2021.11044. Epub 2021 Dec 7.
8
Complete blood count alterations in COVID-19 patients: A narrative review.新型冠状病毒肺炎患者的全血细胞计数改变：一篇叙述性综述。
Biochem Med (Zagreb). 2021 Oct 15;31(3):030501. doi: 10.11613/BM.2021.030501.
9
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.COVID-19 相关毛霉菌病：全球及印度病例报告的系统综述。
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102146. doi: 10.1016/j.dsx.2021.05.019. Epub 2021 May 21.
10
Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection.用于严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）/COVID-19 检测的工具和技术。
Clin Microbiol Rev. 2021 May 12;34(3). doi: 10.1128/CMR.00228-20. Print 2021 Jun 16.